An important milestone for people with secondary progressive MS in Europe
EMA conducts safety review of alemtuzumab (Lemtrada)
FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS
FDA approves the drug Siponimod, to treat people with active secondary progressive MS
Third annual meeting (Encuentro) brings together MS organisations from 16 Latin American countries to share learnings and work towards shared solutions to common challenges.